Production, Radiolabeling and Biodistribution Studies of 175Yb-DOTMP as Bone Pain Palliation 175Yb-DOTMP as bone pain palliation
Iranian Journal of Pharmaceutical Sciences,
Vol. 8 No. 2 (2012),
1 April 2012
,
Page 135-141
https://doi.org/10.22037/ijps.v8.40959
Abstract
Bone is the third most common site of metastatic disease. Bone pain is the major source of morbidity associated bone metastasis. Bone-seeking radiopharmaceuticals have been applied for many years. The ability to simultaneously treat multiple sites of disease with a more probable therapeutic effect in earlier phases of metastatic disease is one of the advantages of radiopharmaceuticals. 175Yb is one
of the radioisotopes with suitable properties for developing various nuclear medicine agents. Some of these proper properties include 4.2 days half-life, gamma-rays emitted, radionuclidic purity. Radiopharmaceuticals capable of targeting bone tumors generally use phosphonic acid functionality as the targeting moiety. In this direction cyclic tetraphosphonate, 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraaminomethylenephosphonate (DOTMP) has been labeled with 175YbCl3. Production, quality control and biodistribution studies of 175Yb-DOTMP were targeted in this study. 175Yb chloride with mean specific activity of 31 mCi/mg was obtained by thermal neutron flux (3×1013 n.cm-2.s-1) of a natural Yb2O3 sample (isotopic purity of 31.8% for 174Yb) in the Tehran Research Reactor (TRR). Radiolabeling was completed in one h by the addition of DOTMP at room temperature. The radiochemical purity was determined using ITLC and it was more than 98%. The results of biodistribution animal studies are excellent. It was rapidly taken up in the bone in 2 h after injection (ID/g%=3.92) and reminded after 4 d (ID/g%=3.91).
- Biodistribution
- Bone Metastases
- DOTMP
- Radiopharmaceutical
- Ytterbium-175
How to Cite
References
[2] Clines G, Guise T. Mechanisms and treatment for bone metastases. Clin Adv Hematol Oncol 2004; 2: 295-302
[3] Casciato DA, Territo MC. Manual of clinical oncology, Lippincott Williams & Wilkins; London;2008:151-3.
[4] Hillegonds DJ, Franklin S, Shelton DK, Vijayakumar S, Vijayakumar V. The management of painful bone metastases with an emphasis on radionuclide therapy. J Natl Med Assoc 2007; 99: 785-94
[5] Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001;42:895-906.
[6] Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, Giammarile F. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imag 2008; 35: 1934-40.
[7] Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004; 45:1358-65.
[8] Chakravarty R, Das T, Venkatesh M, Dash A. An electro-amalgamation approach to produce 175Yb suitable for radiopharmaceutical applications. Radiochim Acta 2012;100:4:255-61.
[9] Taylor D, Leggett R. A generic biokinetic model for predicting the behaviour of the lanthanide elements in the human body. Rad Protec Dosimet 2003; 105: 193-8
[10] Firestone RB, Chu S, Baglin CM. of the Table of Isotopes: 1998 Update. In: editor.^editors.: 1997.p.
[11] Chakraborty S, Unni P, Venkatesh M, Pillai M. Feasibility study for production of 175Yb: a promising therapeutic radionuclide. Appl Rad Isotopes 2002; 57: 295-301.
[12] Mathew B, Chakraborty S, Das T, Sarma H, Banerjee S, Samuel G, Venkatesh M, Pillai M. 175Yb labeled polyaminophosphonates as potential agents for bone pain palliation. Appl Rad Isotopes 2004; 60: 635-42.
[13] Das T, Chakraborty S, Unni P, Banerjee S, Samuel G, Sarma H, Venkatesh M, Pillai M. 177Lulabeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl Rad Isotopes 2002; 57: 177-84.
[14] Volkert WA, Hoffman TJ. Therapeutic radiophar maceuticals. Chem Rev 1999; 99: 2269-92.
[15] Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium (III) chelates as MRI contrast agents:structure, dynamics, and applications. Chem Rev 1999; 99: 2293-352.
- Abstract Viewed: 267 times
- IJPS_Volume 8_Issue 2_Pages 135-141 Downloaded: 209 times